Spots Global Cancer Trial Database for Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
Official Title: Cabozantinib and Pembrolizumab as a Front-line Therapy for Advanced Metastatic Melanoma
Study ID: NCT03957551
Conditions
Study Description
Brief Summary: The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
Detailed Description: This is an open-label, Phase 1b/2 trial for adults with advanced melanoma. The objective of the Phase 1b portion of the study is to establish the recommended Phase 2 dose of cabozantinib in combination with pembrolizumab in patients with unresectable melanoma and assess the safety and tolerability of the combined treatments. The objective of the Phase 2 portion of the study is to evaluate the preliminary efficacy of the established dose of cabozantinib in combination with pembrolizumab as measured by best overall response rate (ORR) (complete response \[CR\] + partial response \[PR\]) with the combination of agents in patients with unresectable stage III or stage IV melanoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Contact Details
Name: Yousef Zakharia, MD
Affiliation: University of Iowa
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
